SECsense Logo

Lyell Immunopharma 8-K/A Report: Key Updates for Investors (LYEL)

$LYEL
Form 8-K/A
Filed on: 2025-01-10
Source
Lyell Immunopharma 8-K/A Report: Key Updates for Investors (LYEL)

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Entity Information:
  • Company Name: Lyell Immunopharma, Inc.
  • CIK Number: 0001806952
  • Stock Ticker: LYEL
  • Exchange: NASDAQ
  • Company Address: 201 Haskins Way, South San Francisco, CA 94080
  • Contact Number: 650-695-0677
  1. Filing Details:
  • Filing Type: 8-K/A (Amendment to the current report on Form 8-K)
  • Filing Date: October 31, 2024
  1. Financial Metrics:
  • Common Stock: Par value of $0.0001 per share
  1. Context Information:
  • Period Covered: The report pertains to a single day, October 31, 2024.

Insights:

  • The filing indicates that Lyell Immunopharma is likely providing updated or additional information related to a significant event or change that warrants an amendment to a previous 8-K filing.
  • The timing of the report (end of October 2024) suggests that it may be tied to the company's quarterly reporting cycle or a specific event impacting financials or operations.
  • The mention of common stock with a low par value indicates that the company may be in a growth phase, common for biotech firms which often have lower par values for their shares. This could reflect on their strategy for attracting investment.

Conclusion:

This section of the financial report provides crucial information about the company’s filing status, its basic corporate structure, and regulatory compliance as it relates to recent significant events. Further analysis would require additional context or details from the 8-K/A document itself to understand the specifics of the amendments or disclosures made.